Actively Recruiting
Multicenter, Dose-Escalation and Dose-Expansion, Single-Arm, Open-Label Phase I Trial to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TSL2109 Capsules in Advanced Solid Tumor Patients
Led by Tasly Pharmaceutical Group Co., Ltd · Updated on 2026-04-07
78
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating TSL2109, a new drug that targets specific proteins CDK46 and DYRK2 involved in the growth of solid tumors. It is designed to work in cases where other treatments, like palbociclib and androgen receptor inhibitors, have stopped working. This drug aims to help patients with metastatic castration-resistant prostate cancer mCRPC and hormone receptor-positive, HER2-negative advanced breast cancer who have limited treatment options. The study is a Phase 1 trial focusing on safety, tolerability, and early signs of effectiveness. The study includes a Dose-Escalation Phase where participants receive increasing doses of TSL2109 capsules orally while fasting. Initial dosing involves a single dose followed by a 72-hour observation period. Subsequent treatment cycles last 28 days, with daily dosing for 3 weeks followed by a 1-week break. Dose levels may be adjusted if the drug is well tolerated and potentially beneficial. The Dose-Expansion Phase uses the same regimen to further evaluate the drug at doses up to the maximum tolerated dose MTD. Participants will be monitored closely for tolerability and drug levels in their blood within 31 days after dosing. They will undergo tumor assessments based on standardized criteria, and treatment will continue until disease progression, unacceptable side effects, or the start of another cancer therapy. The study includes detailed observation of dose-limiting toxicities and allows dose adjustments to optimize treatment. Total participation length varies depending on individual responses and treatment continuation.
CONDITIONS
Brief Title
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy
Research Team
R
Rui Liu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here